$ENLV

Enlivex Ltd.

Enlivex is an Israel-based company with principal executive offices in Ness Ziona. It develops therapies focused on extending health span and improving quality of life, with clinical operations centered on osteoarthritis, and operates a digital asset treasury strategy involving the RAIN protocol. Its lead therapeutic candidate, Allocetra, is a macrophage reprogramming therapy designed to restore immune balance and address inflammatory and degenerative conditions associated with aging. The company is preparing a Phase IIb trial of Allocetra injections for age-related primary knee osteoarthritis. Enlivex’s treasury strategy is anchored in RAIN, a decentralized prediction markets and options protocol built on Arbitrum. RAIN allows users to create and trade custom prediction markets, and its token is used for governance. Enlivex holds RAIN and may pursue staking, liquidity provision, market participation and other DeFi activities. It may also earn trading fees, secondary-market spreads or protocol incentives through participation in RAIN markets.

2
0
1

No SEC Form 4 filings for $ENLV in the last 30 days.

See all $ENLV insider activity →
Med

Enlivex Reports Durable 12-Month Response With Allocetra In Knee Osteoarthritis Trial

Enlivex (ENLV) reported 12-month Phase I/IIa trial results for Allocetra, showing 79.2% of older patients with knee osteoarthritis experienced reduced pain and improved function vs. 47.6% with placebo. The therapy demonstrated a favorable safety profile. The company plans to present findings at ACR Convergence 2026 and expects Phase IIb trial data by Q2 2027. ENLV stock closed at $1.15, up 2.68%.

Enlivex raises $7.5 million in registered direct offering

Enlivex Ltd. (NASDAQ:ENLV) raised $7.5 million in a registered direct offering, selling shares and warrants at a 10.5% premium. The funds will support clinical, regulatory, and R&D activities. The offering is expected to close in stages, with the first closing at $500,000. Investors may receive 5% of certain payments from commercial transactions.

ENLV sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 3 news stories mentioning ENLV (Enlivex Ltd.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 1 bearish.

Recent ENLV coverage spans corporate actions, technology and regulation.

What's driving ENLV

AlphAI scores every news story that mentions ENLV with an AI model for sentiment and relevance, and aggregates insider trades from Enlivex Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $ENLV

Score

Enlivex Reports Durable 12-Month Response With Allocetra In Knee Osteoarthritis Trial

Enlivex (ENLV) reported 12-month Phase I/IIa trial results for Allocetra, showing 79.2% of older patients with knee osteoarthritis experienced reduced pain and improved function vs. 47.6% with placebo. The therapy demonstrated a favorable safety profile. The company plans to present findings at ACR Convergence 2026 and expects Phase IIb trial data by Q2 2027. ENLV stock closed at $1.15, up 2.68%.

Weekly Buzz: AZN, ALVO Score FDA Nod; EYPT Cuts Jobs; RHHBY, GEHC Enter Deal; VERA Posts Trial Win

AstraZeneca (AZN) received FDA approval for Ultomiris in IgA nephropathy, with a 43.4% reduction in proteinuria. Merck (MRK) got EU approval for KEYTRUDA plus Padcev in bladder cancer, showing a 35% reduction in death risk. Alvotech (ALVO) approved a new manufacturing process for SIMLANDI. Cytokinetics (CYTK) won Health Canada approval for MYQORZO in obstructive HCM. Viatris (VTRS) approved RYZUMVI for presbyopia. Enlivex (ENLV) and EyePoint (EYPT) announced significant workforce reductions.

Related tickers